12 Apr 2018 --- DSM has pre-announced better-than-expected earnings for the first quarter and raised its 2018 outlook on upbeat sales, with an additional boost from high prices in vitamins. The first quarter benefited from an additional Adjusted EBITDA contribution estimated at €165 million from an exceptional vitamin pricing environment. DSM raised its 2018 adjusted EBITDA forecast to "toward" 25 percent from earlier guidance for a rise of at least high single-digit growth.
